Deng Rongrong, He Kaiying, You Qicai, Zhang Wenkai, Ma Xuezhen, Zhou Xiaochun, Kong Yuke, Wang Janqin
Lanzhou University, Lanzhou, 730030, Gansu, China.
Department of Nephrology, The Second Hospital & Clinical Medical School, Lanzhou University, No. 82, Cuiyingmen, Lanzhou, 730030, Gansu, China.
Eur J Med Res. 2025 Jul 29;30(1):682. doi: 10.1186/s40001-025-02932-6.
Cardiotrophin-like cytokine factor 1 (CLCF1) is shown to enhance glomerular albumin permeability, contributing to proteinuria. However, its specific involvement in diabetic kidney disease (DKD) remains undefined. This study aimed to explore the mechanistic contribution of CLCF1 to endothelial-to-mesenchymal transition (EndMT) in DKD.
CLCF1 expression in patients with DKD and high glucose (HG)-stimulated human glomerular endothelial cells (HRGECs) was quantified via quantitative real-time polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry (IHC). The effects of CLCF1 on HG-induced EndMT and the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling cascade were assessed through qRT-PCR and Western blot analysis. Additionally, the role of JAK2/STAT3 activation in mediating EndMT was examined using the JAK2/STAT3 agonist colivelin in CLCF1-knockdown HRGECs.
In patients with DKD and HG-stimulated HRGECs, CLCF1 mRNA and protein expression were elevated (p < 0.001 and p < 0.001 for mRNA; p < 0.001 and p < 0.001 for protein). CLCF1 knock- down attenuated HG-induced EndMT, as evidenced by reduced α-Smooth Muscle Actin(α-SMA) and vimentin expression (qRT-PCR/Western blot: α-SMA: p < 0.001 for both; vimentin p < 0.001/ p = 0.004). Conversely, CLCF1 overexpression promoted EndMT and activated the JAK2/STAT3 pathway, with concordant qPCR (α-SMA: p < 0.001 for both; vimentin: p < 0.001 for both) and Western blot (α-SMA: p < 0.001; vimentin: p < 0.001; p-JAK2: p = 0.010; p-STAT3: p = 0.005). Notably, the protective effect of CLCF1 knockdown was abolished by colivelin.
These findings demonstrate that CLCF1 mediates HG-induced EndMT in HRGECs via modulation of the JAK2/STAT3 pathway. This indicates that the CLCF1/JAK2/STAT3 signaling axis plays a role in the pathogenesis of DKD.
类心肌营养素细胞因子1(CLCF1)被证明可增强肾小球白蛋白通透性,导致蛋白尿。然而,其在糖尿病肾病(DKD)中的具体作用仍不明确。本研究旨在探讨CLCF1在DKD中对内皮-间充质转化(EndMT)的作用机制。
通过定量实时聚合酶链反应(qRT-PCR)、蛋白质印迹法和免疫组织化学(IHC)对DKD患者及高糖(HG)刺激的人肾小球内皮细胞(HRGECs)中CLCF1的表达进行定量分析。通过qRT-PCR和蛋白质印迹分析评估CLCF1对HG诱导的EndMT及Janus激酶2/信号转导子和转录激活子3(JAK2/STAT3)信号级联反应的影响。此外,在CLCF1敲低的HRGECs中使用JAK2/STAT3激动剂可立维林检测JAK2/STAT3激活在介导EndMT中的作用。
在DKD患者及HG刺激的HRGECs中,CLCF1 mRNA和蛋白表达均升高(mRNA:p < 0.001和p < 0.001;蛋白:p < 0.001和p < 0.001)。CLCF1敲低减弱了HG诱导的EndMT,α-平滑肌肌动蛋白(α-SMA)和波形蛋白表达降低证明了这一点(qRT-PCR/蛋白质印迹法:α-SMA:两者均为p < 0.001;波形蛋白:p < 0.001/p = 0.004)。相反,CLCF1过表达促进了EndMT并激活了JAK2/STAT3通路,qPCR(α-SMA:两者均为p < 0.001;波形蛋白:两者均为p < 0.001)和蛋白质印迹法(α-SMA:p < 0.001;波形蛋白:p < 0.001;p-JAK2:p = 0.010;p-STAT3:p = 0.005)结果一致。值得注意的是,可立维林消除了CLCF1敲低的保护作用。
这些发现表明,CLCF1通过调节JAK2/STAT3通路介导HG诱导的HRGECs中的EndMT。这表明CLCF1/JAK2/STAT3信号轴在DKD的发病机制中起作用。